Early triple-negative breast cancer in women aged ≥65: retrospective study of outcomes, resource use and costs, 2010–2016

Pembrolizumab for Early Triple-Negative Breast Cancer

(2020) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Breast Cancer Treatment

(2019) Adrienne G. Waks et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Overall survival, costs and healthcare resource use by number of regimens received in elderly patients with newly diagnosed metastatic triple-negative breast cancer

(2019) Abdalla Aly et al.   Future Oncology

Future of checkpoint blockade in triple-negative breast cancer: combination strategies to lead the way

(2019) M L Telli et al.   ANNALS OF ONCOLOGY

Adjuvant treatment and survival in older women with triple negative breast cancer: A Surveillance, Epidemiology, and End Results analysis

(2019) Margaret M. Kozak et al.   Breast Journal

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2019) F Cardoso et al.   ANNALS OF ONCOLOGY

Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers

(2019) Lajos Pusztai et al.   LANCET ONCOLOGY

Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States

(2018) Kendra L. Schwartz et al.   CANCER

Differences in Breast Cancer Survival by Molecular Subtypes in the United States

(2018) Nadia Howlader et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Using oncology real-world evidence for quality improvement and discovery: the case for ASCO's CancerLinQ

(2018) Robert S Miller et al.   Future Oncology

Real-world Data for Clinical Evidence Generation in Oncology

(2017) Sean Khozin et al.   JNCI-Journal of the National Cancer Institute

Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0

(2017) Shirley V. Wang et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making

(2017) Marc L. Berger et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Real-world Data for Clinical Evidence Generation in Oncology

(2017) Sean Khozin et al.   JNCI-Journal of the National Cancer Institute

Cancer Incidence and Survival Trends by Subtype Using Data from the Surveillance Epidemiology and End Results Program, 1992–2013

(2016) Anne-Michelle Noone et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Overview of breast cancer collaborative stage data items-their definitions, quality, usage, and clinical implications: A review of SEER data for 2004-2010

(2014) Nadia Howlader et al.   CANCER

US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status

(2014) Nadia Howlader et al.   JNCI-Journal of the National Cancer Institute

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry

(2012) Onur Baser et al.   CURRENT MEDICAL RESEARCH AND OPINION